Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY517717 vs Enoxaparin for VTE Prevention Post-Hip/Knee Replacement
NCT00074828Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2003
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of LY-517717 in venous thromboembolism (VTE) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Proportion of patients with VTE event (DVT and/or PE). Started Dec 2003; status: completed.
02
Drugs
LY-517717
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00074828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00074828.